All In Biotech

Free tool

FAERS Monitor: Darzalex Faspro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761145 or its brand name (Darzalex Faspro, Daratumumab and Hyaluronidase-Fihj). Reports on generic versions are filed under their own applications.

Reports

3,064

Serious

1,414

46% of reports

Hospitalization

462

Death reported

121

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue225
  • product dose omission issue223
  • off label use210
  • rash163
  • diarrhoea141
  • nausea118
  • dyspnoea105
  • neuropathy peripheral104
  • neutropenia91
  • plasma cell myeloma90
  • death86
  • dizziness76
  • pyrexia76
  • pneumonia74
  • white blood cell count decreased70

Reports by year received

View as table
YearReports
20161
20191
2020105
2021328
2022511
2023521
2024556
2025570
2026471

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,095 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
plasma cell myelomaSignal9015.912.91,239
neuropathy peripheralSignal1047.56.2583
product dose omission issueSignal2235.24.6764
neutropeniaSignal914.63.8254
white blood cell count decreasedSignal704.43.5184
rashSignal1632.62.2158
fatigue2252.01.7113
off label use2101.61.455
pneumonia741.61.315
pyrexia761.51.213
diarrhoea1411.51.324
dyspnoea1051.31.16
dizziness761.00.80
nausea1181.00.90
death860.70.613

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.